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Background: In patients with chronic obstructive pulmonary disease (COPD), the
inflammatory processes and oxidative stress are closely linked in the lung compartment.
However, the relationships between systemic inflammation and parameters of oxidative
stress in the systemic circulation during acute exacerbations of COPD remain to be
explored.
Objective: To analyze relationships between erythrocytic glutathione peroxidase (GPx), a
marker of systemic oxidative stress, and parameters reflecting systemic inflammation,
such as circulating neutrophils, C-reactive protein (CRP), and interleukin (IL)-6, in patients
with acute exacerbations of COPD.
Patients and methods: We measured erythrocytic GPx activity, circulating neutrophil
count, and serum high-sensitivity (hs) CRP and IL-6 in 177 patients admitted to the hospital
due to an acute exacerbation of COPD (91 males, mean age 66.870.9 years, mean FEV1
45.371.3% predicted).
Results: From GOLD Stage II to Stage III and IV, erythrocytic GPx activity significantly
decreased [mean7SEM: from 44.371.7U/g Hb to 40.871.1U/g Hb and to 38.471.5U/g
Hb, p ¼ 0.037], while serum hsCRP increased [median (25th, 75th percentile): from 9.6
(3.0, 23.0)mg/l to 23.3 (6.4, 46.8)mg/l, and to 26.7 (6.5, 117.2)mg/l, p ¼ 0.004].
Erythrocytic GPx activity was significantly inversely related to both, log neutrophil count
(r ¼ 0.219, p ¼ 0.003) and log hsCRP (r ¼ 0.199, p ¼ 0.008).
Conclusions: Our study suggests an association between systemic inflammation and
systemic oxidative stress reflected by erythrocytic GPx in patients with acute exacerba-
tions of COPD.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Systemic inflammation and oxidative stress in COPD 1671Introduction of an exacerbation, participated in the study. The diagnosisMany aspects of the airway and systemic oxidative stress1–4
and airway and systemic inflammation5–9 in chronic ob-
structive pulmonary disease (COPD) have been unraveled in
recent years. Importantly, systemic inflammation may be
involved in the pathogenesis of systemic complications in
patients with COPD.6 In non-COPD patients, several recent
studies reported associations between increased cardiovas-
cular risk, elevated neutrophil count,10,11 and peripheral
markers of oxidative stress.12,13 In addition, it has been
suggested that oxidative stress might be a determinant of
serum C-reactive protein (CRP) levels and promote pro-
atherosclerotic inflammatory processes.14 Therefore, inves-
tigation of systemic oxidative stress in patients with COPD
who are known to be at increased cardiovascular risk15
became particularly relevant.
Recently, we3 and others4 have demonstrated an inverse
relationship between glutathione peroxidase (GPx) activity
in erythrocytes and the degree of obstructive lung impair-
ment in patients with COPD. On the other hand, chronic
airflow limitation is associated with systemic inflammation
as evidenced by significantly raised circulatory levels of CRP,
fibrinogen, leukocytes, and tumor necrosis factor (TNF)-a.6
Importantly, high CRP levels were shown to be associated
with clinically important outcomes such as lower perfor-
mance in the 6-min walk distance test,7 impaired energy
metabolism, respiratory distress,8 and increased mortality.9
Taken together, these data suggest a need to explore a
potential link between systemic oxidative stress and
systemic inflammation in patients with COPD.
Several studies reported that, in the lung compartment,
the inflammatory processes and oxidative stress are tightly
linked.16–18 In patients with stable COPD, significant
relationships were observed between sputum neutrophils
and sputum concentrations of nitrosothiols and oxidized
glutathione,17 and between sputum neutrophils and levels of
hydrogen peroxide and 8-isoprostane in exhaled breath
condensate.18 In addition, associations between parameters
of oxidative stress markers and neutrophilia in the lungs,
and inflammatory cytokines in the systemic circulation were
reported.19 Nevertheless, the data on the potential relation-
ships between systemic inflammation and markers of
systemic oxidative stress in COPD are scarce. In a recent
report, a relationship between GPx in blood and serum
interleukin (IL)-8 in patients with stable COPD was ob-
served.20 Similar relationships have not been yet studied
during acute exacerbations of COPD. Therefore, the aim of
the present study was to analyze relationships between
erythrocytic GPx, a marker of systemic oxidative stress, and
parameters reflecting systemic inflammation, such as
circulating neutrophil count, high-sensitivity (hs) CRP, and
IL-6, in patients with acute exacerbations of COPD.
Patients and methods
Study population
Patients with diagnosis of COPD according to the American
Thoracic Society/European Respiratory Society guidelines,21
admitted to the tertiary referral teaching hospital becauseof an acute exacerbation was established if the patient
suffered from a sustained worsening of his/her conditions
from the stable state, and beyond the normal day-to-day
variations, that was acute in onset and warranted additional
treatment.22 This definition is based on previously described
symptomatic criteria.23,24 In agreement with Perera et al.,25
worsening dyspnea, increase in sputum volume, and
increased sputum purulence were considered major symp-
toms, whereas increased cough or chest tightness, wheeze,
sore throat, and coryza were considered minor symptoms.
An exacerbation was defined as the presence of at least two
major, or one major and one minor symptom, on two or
more consecutive days.22,25,26 Exclusion criteria were
respiratory disorders other than COPD, a new radiological
infiltrate, malignancy, overt cardiac failure, recent surgery,
chronic autoimmune disorders, and severe endocrine,
hepatic or renal disease. Treatment of acute exacerbation
consisted of inhaled bronchodilators, systemic corticoster-
oids, oxygen use in case of hypoxemia, and antibiotics in
case of purulent sputum and/or evidence of microbial
growth in sputum. The study had local ethics committee
approval, and all subjects gave written consent to the study.
Pulmonary function tests
Pulmonary function tests were evaluated with the use of
bodyplethysmography (Ganshorn, Germany). All pulmonary
function testing was performed according to the European
Respiratory Society standards27 with the patients in a sitting
position by the same technician in order to ensure
consistency of the technique. Three technically acceptable
measurements were performed on each patient, and the
highest value was included in the analyses.
Biochemical analyses
In all patients, peripheral venous blood samples from the
antecubital vein were collected between 6.00 and 8.00 a.m.
after 10 h fast, within first 36 h after admission. Arterial
blood gases were determined in samples obtained by
puncture of the radial artery with the patient seated. The
samples for blood gases analyses were obtained while
breathing room air in patients not treated with oxygen,
and while breathing oxygen in those requiring oxygen
therapy. Routine biochemical analyses were performed using
standard techniques. GPx activity was determined in
washed red blood cells obtained immediately after sampling
from the whole blood anticoagulated with EDTA using
commercially available kits (Ransel, Randox). GPx values
are expressed as units per gram hemoglobin (U/g Hb).
Serum was separated from blood cells by centrifugation at
4000 cycles/min. All samples were stored at 70 1C until
analyzed. Hs serum CRP levels were assessed by chemilu-
miniscent immunoassay (Tina-Quant, Roche Diagnostics).
The analytical sensitivity of this CRP assay is 0.1mg/l. Serum
IL-6 levels were measured using commercially available
enzyme-linked immunosorbent assay kits (Beckmann-Coul-
ter Immunotech). The IL-6 assay sensitivity, defined as the
lowest IL-6 concentration significantly different from the
zero standard with a probability of 95%, was 3 pg/ml.
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Data were analyzed using SPSS for Windows software
(version 14.0). Power calculations were performed based
on hsCRP. This variable was chosen based on its clinical
importance in COPD.7–9 Published results of hsCRP patients
with acute exacerbations of COPD reported an average
standard deviation of 3.26 With this information, a power
calculation indicated that we would need at least 44
patients per each GOLD Stage group to detect a difference
of 2mg/l in hsCRP with a power of 80% at a 0.05 significance
level.
The Kolmogorov–Smirnov test of normality was applied.
Exacerbation inflammatory indices not normally distributed
were rendered so by log10 transformation. Continuous
variables are shown as mean7SEM, non-normally distribu-
ted variables as median (25th, 75th percentile). Differences
between groups in normally distributed variables were
tested by one-way analysis of variance (ANOVA) with Tukey
test for post hoc pairwise comparison procedures, and in
non-normally distributed variables by ANOVA on ranks with
Dunn’s test for post hoc pairwise comparison procedures.
Chi-square test was used to compare the proportion of
categoric variables between groups. To assess the relation-
ships between selected variables, linear regression analysis
was used. Because the distributions of peripheral neutrophil
count, serum hsCRP, and IL-6 activity were all skewed, we
used the log-transformed values of these variables in
regression analyses.Table 1 Demographic data and pulmonary function parameter
Variable Entire group GOLD Stage
II
Number of patients 177 47
Women (no., %) 48 (27) 22 (47)
Age (years) 65.870.8 62.871.8
Smoking (pack-years) 25.571.7 17.973.2
BMI (kg/m2) 25.670.5 26.270.8
FEV1 (% predicted) 41.971.0 60.871.2
FEV1 (l) 1.170.03 1.570.1
FVC (%) 65.871.4 84.171.8
FVC (l) 2.270.1 2.770.1
FEV1/FVC (%) 50.670.9 58.271.0
RV (%) 178.774.2 156.075.0
RV (l) 4.070.1 3.370.1
TLC (%) 108.471.7 107.972.1
TLC (l) 6.470.2 6.270.2
RV/TLC (%) 62.570.9 54.571.2
PaO2 (kPa) 8.270.1 8.970.2
PaCO2 (kPa) 5.670.1 4.870.1
Values given as mean7SEM.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, for
PaCO2, arterial carbon dioxide partial pressure; PaO2, arterial oxyge
P-value refers to trend from GOLD Stage II, to Stage III and to Stage
po0.05 versus GOLD Stage II.
ypo0.05 versus GOLD Stage III.Results
Subjects characteristics
One hundred and seventy-seven patients (129 males and
48 females) with COPD were recruited to the study
(Table 1). Forty-seven patients were classified as
Stage II, 90 patients were Stage III, and 40 patients
were Stage IV COPD.21 All patients had a previous history
of the diagnosis of COPD, and were using short-acting
bronchodilators (salbutamol or ipratropium bromide) to
relieve their symptoms. In addition, 60% of patients were
on long-term treatment with long-acting beta agonists, 58%
with inhaled corticosteroids, 65% with theophyllines, 9%
with oral corticosteroids, and 12% with long-term home
oxygen therapy. Prior to the hospital admission, 15% were
prescribed antibiotics for respiratory infection. The acute
exacerbation of COPD required new or increased adminis-
tration of both bronchodilators and systemic corticosteroids
in all patients. Antibiotics were increased or introduced to
the treatment in 86% patients, and oxygen therapy in 24%
patients. At admission, patients were treated with hydro-
cortisone 200mg intravenously per day, and the dose was
reduced after 2–3 days. None of the patients smoked
cigarettes during the admission. Medical records revealed
an increased prevalence of ischemic heart disease from
Stage II to Stage III and to Stage IV [from 21 (45%) to 60
(67%), and to 20 (50%) patients, p ¼ 0.028]. No differences
were observed between Stage II, III, and IV in the presences in patients with COPD.
III IV P value
90 40
16 (18) 10 (25) 0.002
67.071.1 67.271.4 0.072
29.072.5 26.472.9 0.020
26.170.7 24.070.9 0.146
39.170.6 25.870.5,y o0.001
1.170.1 0.770.1,y o0.001
63.671.4 49.472.3,y o0.001
2.270.1 1.770.1,y o0.001
49.771.1 43.771.9,y o0.001
177.375.7 206.7710.6,y o0.001
4.170.2 4.670.3,y o0.001
107.772.5 110.774.6 0.768
6.470.2 6.770.4 0.567
63.971.0 69.572.1,y o0.001
8.370.2 7.670.3 0.002
5.670.2 6.670.2,y o0.001
ced vital capacity; RV, residual volume; TLC, total lung capacity;
n partial pressure.
IV (ANOVA).
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Figure 1 Activity of glutathione peroxidase (GPx) in erythro-
cytes (mean7SEM) in patients with chronic obstructive pul-
monary disease grouped by GOLD Stages; p for trend ¼ 0.037.
Systemic inflammation and oxidative stress in COPD 1673of arterial hypertension [29 (61%) versus 52 (58%), and
versus 18 (45%), respectively, p ¼ 0.259].
All patients experienced worsened dyspnea as a manifes-
tation of acute exacerbation of COPD, and reported the
average modified MRC dyspnea score of 3.070.1 (‘‘stops for
shortness of breath after walking about 100 meters or after
a few minutes on the level’’). The majority also experienced
worsening cough (79%), an increase in sputum produc-
tion (77%) or a change in sputum color (51%). Wheezing
was reported by 48%, sore throat or coryza by 2% of
patients. Body temperature was increased (437 1C) in 34%
patients. The reported duration of symptoms averaged
2.670.4 days before hospital admission. Sputum cultures
were obtained from 159 of 177 patients. Of these,
potentially pathogenic microorganisms were revealed in 49
(31%): Haemophilus influenzae in 15, Escherichia coli in 10,
Pseudomonas aeruginosa in 6, Acinetobacter in 6, Enter-
obacteriaceae in 4, Klebsiella pneumoniae in 3, Strepto-
coccus pneumoniae in 3, and Staphylococcus aureus in 2
patients.
Peripheral neutrophil count ranged from 1.68 to
19.7 109 l1 with a median of 5.56 109 l1, while IL-6
value ranged from 1.2 to 350.0 pg/ml with a median of
14.7 pg/ml, and hsCRP ranged from 0.1 to 282.8mg/l with a
median of 17.9mg/l. The activity GPx ranged from 20.9 to
74.1 U/g Hb with a median of 39.5 U/g Hb.
Table 1 displays demographic data, pulmonary function
tests, PaO2 and PaCO2 in the GOLD Stage II–IV groups of
patients. The proportion of women was significantly higher
in Stage II compared to Stage III and Stage IV groups
(p ¼ 0.003). In addition, there was a trend towards lower
age in Stage II compared to Stage III and IV groups
(p ¼ 0.072). PaO2 decreased, whereas PaCO2 increased from
Stage II to Stage III and Stage IV group (p ¼ 0.002 and
po0.001, respectively).Figure 2 Serum high-sensitivity C-reactive protein (CRP)
[median (25th, 75th percentile)] in patients with chronic
obstructive pulmonary disease grouped by GOLD Stages; p for
trend ¼ 0.004.Relationships between GOLD Stage, circulating
neutrophil count, serum hsCRP, IL-6, and
erythrocyte GPx activity
From GOLD Stage II to Stage III and IV, erythrocytic GPx
activity significantly decreased [mean7SEM: from
44.371.7U/g Hb to 40.871.1 U/g Hb and to 38.471.5 U/g
Hb, p ¼ 0.037] (Fig. 1), while serum hsCRP increased
[median (25th, 75th percentile): from 9.6 (3.0, 23.0)mg/l
to 23.3 (6.4, 46.8)mg/l, and to 26.7 (6.5, 117.2)mg/l,
p ¼ 0.004] (Fig. 2). No differences were observed in either
circulating neutrophil count or serum IL-6 between the
three GOLD Stages [circulating neutrophil count: 5.5 (1.1,
7.9) versus 5.7 (4.2, 8.0) versus 5.6 (4.2, 8.7) 109 l1,
p ¼ 0.487; IL-6: 16.8 (8.4, 33.2) pg/ml versus 15.5 (10.6,
37.1) pg/ml, and versus 12.8 (8.0, 25.0) pg/ml, p ¼ 0.550].
Table 2 displays linear relationships between FEV1, GPx,
and log-transformed values of inflammatory markers.
Importantly, erythrocytic GPx activity was significantly
inversely related to both, log hsCRP (p ¼ 0.008) and log
neutrophil count (p ¼ 0.003) (Fig. 3). Also, a relationship
between log neutrophil count and log hsCRP was observed
(r ¼ 0.247, po0.001). Furthermore, GPx activity was
related to FEV1 (r ¼ 0.233, p ¼ 0.002).Discussion
The present study provides a novel observation of the
relationships between markers of systemic inflammation and
GPx, a parameter of systemic oxidative stress, during acute
exacerbations of COPD: erythrocytic GPx activity was
inversely related to log-transformed serum hsCRP. In
addition, circulating neutrophils were inversely related to
GPx activity, and directly to hsCRP levels. A close link
between oxidative stress and inflammatory processes was
recognized in the lung compartment of patients with COPD
before.16–18 Our data extend these previous findings by
demonstrating that oxidative stress is related to inflamma-
tory markers also in the systemic compartment.
In the lung compartment, the links between inflammatory
processes and oxidative stress were studied repeatedly by
analyzing various inflammatory markers and parameters of
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Table 2 Linear relationships [r (P-value)] between
FEV1, glutathione peroxidase (GPx) activity in erythro-
cytes, and log-transformed circulating neutrophil count,
serum high-sensitivity C-reactive protein (hsCRP) and
interleukin-6 concentrations.
Variable FEV1 (%
predicted)
GPx (U/g Hb)
Neutrophils
(log cells 109 l1)
0.120 (0.114) 0.219 (0.003)
hsCRP (logmg/l) 0.312 (o0.001) 0.199 (0.008)
Interleukin-6 (log pg/
ml)
0.073 (0.414) 0.087 (0.333)
FEV1, forced expiratory volume in 1 s; GPx, glutathione
peroxidase; hsCRP, high-sensitivity C-reactive protein.
Figure 3 Relationship between erythrocytic glutathione per-
oxidase activity and log-transformed high-sensitivity C-reactive
protein (r ¼ 0.199, p ¼ 0.008), and between erythrocytic
glutathione peroxidase activity and log-transformed neutrophil
count (r ¼ 0.219, p ¼ 0.003) in the entire group of 177
patients with an acute exacerbation of COPD.
R. Tkacova et al.1674oxidative stress in induced sputum or exhaled breath
condensate. In healthy individuals, sputum induction with
hypertonic saline causes an inflammatory response that isparalled by increases in exhaled nitric oxide concentra-
tions.28 In patients with stable COPD, Beeh et al.17 reported
a significant relationship between sputum neutrophilia, and
sputum concentrations of nitrosothiols and oxidized glu-
tathione; Kostikas et al.18 observed analogical associations
between sputum neutrophils and levels of hydrogen per-
oxide and 8-isoprostane in the exhaled breath condensate.
Prominent neutrophilia has been described in bronchoalveo-
lar lavage fluid and induced sputum from patients with
COPD,29 and neutrophilic infiltration within the smooth
muscle of such patients may have a pathogenetic role of
smoking-induced airflow limitation.30 Importantly, the en-
hanced oxidative stress within the airways is paralleled by
activation of neutrophils and their increased ability to
synthesize chemotactic factors such as leukotriene B4.31
Therefore, it has been suggested that oxidative stress in vivo
enhances local inflammation, and may ultimately contribute
to the infiltration/activation of neutrophils into the airways
of subjects with COPD.31
Associations between parameters of oxidative stress
markers in the lungs and inflammatory cytokines in the
systemic circulation were also reported. In exacerbated
COPD patients, raised levels of hydrogen peroxide in the
exhaled air, in association with increased serum IL-8 and cell
adhesion molecules at admission were observed.19 During
subsequent treatment, all the markers significantly de-
clined.19 Nevertheless, the data on the potential relation-
ships between systemic inflammation and markers of
systemic oxidative stress in COPD are scarce. In a recent
report, Sadowska et al.20 observed a significant relationship
between GPx in blood and serum IL-8 in patients with stable
COPD. In our study, we have demonstrated an inverse
relationship between the circulating neutrophil count and
erythrocytic GPx activity, and a direct relationship between
neutrophil count and log-transformed serum hsCRP. Impor-
tantly, GPx activity was inversely related to log-transformed
hsCRP levels. Therefore, our study provides a novel evidence
of significant relationships between oxidative stress and
systemic inflammation markers during acute exacerbations
of COPD, complementary to those observed in patients with
stable disease before.20
Findings of the present study might be meaningful
especially in the light of three recently published sets of
observations. First, population-based studies suggest that
elevated white blood cell count is directly associated with
increased incidence of coronary heart disease, ischemic
stroke, and death from cardiovascular disease,10 with
greater predictive ability provided by high neutrophil count
compared to total white blood cell count.11 Second,
considerable amount of data indicates the clinical impor-
tance and predictive value of CRP in patients with COPD:
high CRP levels correlate with poorer performance in the 6-
min walk distance test,7 impaired energy metabolism,
respiratory distress8 and, in addition, they relate to
increased mortality.9 Third, peripheral markers of oxidative
stress were shown repeatedly to be related to increased
cardiovascular risk in non-COPD patients. Elevated levels of
antioxidative enzyme myeloperoxidase in the blood, in
association with increased leukocyte count, were associated
with increased risk of coronary artery disease,12 whereas
depletion of the GPx activity in erythrocytes was indepen-
dently associated with an increased risk of cardiovascular
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be a determinant of CRP levels and promote pro-athero-
sclerotic inflammatory processes.14 To date, no data are
available on the potential relationship between reduced
erythrocytic GPx as a marker of systemic oxidative stress,
and increased cardiovascular risk in patients with COPD.
Importantly, given the current knowledge on the association
between cardiovascular risk and CRP or GPx, several
observations of the present study might stimulate future
research to address this issue: first, we demonstrated a link
between increased hsCRP and reduced GPx activity; second,
an inverse relationship between FEV1 and hsCRP, and a
direct relationship between FEV1 and erythrocytic GPx
activity were observed; third, a significant trend towards
higher prevalence of ischemic heart disease with increased
COPD severity was seen, in agreement with previous
reports.32
There are several limitations to this study. The study was
based on observational cross-sectional data, and therefore
it remains uncertain whether clinical improvement during
acute COPD exacerbations results in reductions in systemic
inflammation in association with the restoration of systemic
antioxidative mechanisms. Furthermore, treatment with
systemic corticosteroids at the admission could have
affected neutrophil counts in our study. Nevertheless, since
all patients were treated by steroids using the same
treatment regimen, the differences in the neutrophil
counts, GPx, and CRP observed between the different GOLD
Stages are relevant. It has to be emphasized that our study
was not designed and powered to analyze a series of serum
biomarkers and their correlation with clinical parameters. In
a recent report, Pinto-Plata et al.33 demonstrated that a
panel of 25 serum biomarkers was significantly related to
FEV1, diffusion capacity, physical performance, and exacer-
bation frequency. Our data raise a question whether
parameters of systemic oxidative stress such as erythrocytic
GPx could potentially represent additional markers of
important clinical outcomes in patients with COPD. Such a
hypothesis requires to be tested in future studies.
In conclusion, the present study in patients with acute
exacerbations of COPD demonstrates a link between
erythrocytic GPx activity, a parameter of systemic oxidative
stress, and serum CRP—a clinically important marker of
systemic inflammation. This observation may have several
potential implications, and raises some intriguing questions.
First, these observations suggest that inflammation and
oxidative stress are co-dependent and strongly interrelated
processes not only in the lung16–18 but also in the systemic
compartment. Second, a question regarding the origin of
systemic oxidative stress, and its relationship to the origin of
systemic inflammation remains to be explored. Further
studies are needed to address these questions in more
details.Acknowledgments
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